Decreased number and reduced NKG2D expression of Vδ1 γδ T cells are involved in the impaired function of Vδ1 γδ T cells in the tissue of gastric cancer

Gastric Cancer

Volumn 15, Issue 4, 2012, Pages 433-439

  Kuroda, Hirohiko ^a   Saito, Hiroaki ^a   Ikeguchi, Masahide ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

T cells; Gastric cancer; Immune evasion; NKG2D

Indexed keywords

GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D;

AGED; ARTICLE; CANCER TISSUE; CELL ISOLATION; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; V DELTA 1 GAMMA DELTA T LYMPHOCYTE; V DELTA 2 GAMMA DELTA T LYMPHOCYTE; V DELTA 9 GAMMA DELTA T LYMPHOCYTE;

AGED; CASE-CONTROL STUDIES; FEMALE; GASTRIC MUCOSA; HUMANS; INTERFERON-GAMMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REFERENCE VALUES; STOMACH NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 84870353892     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0138-x     Document Type: Article

References (28)

1. Kabelitz D, Wesch D, Pitters E, Zoller M. Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer. 2004;112: 727-32.
2. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18: 975-1026.
3. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001;294: 605-9.
4. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16: 3-15.
5. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer. 1998;1: 10-24.
6. Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, et al. Human intestinal Vdelta1? lymphocytes recognize tumor cells of epithelial origin. J Exp Med. 1996;183: 1681-96.
7. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumorderived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA. 1999;96: 6879-84.
8. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by transretinoic acid. Cancer Res. 2004;64: 9172-9.
9. Glienke J, Sobanov Y, Brostjan C, Steffens C, Nguyen C, Lehrach H, et al. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics. 1998;48: 163-73.
10. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3: 781-90.
11. Watzl C. The NKG2D receptor and its ligands-recognition beyond the "missing self"? Microbes Infect. 2003;5: 31-7.
12. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol. 2002;14: 306-11.
13. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285: 727-9.
14. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419: 734-8.
15. Osaki T, Saito H, Yoshikawa T, Matsumoto S, Tatebe S, Tsujitani S, et al. Decreased NKG2D expression on CD8? T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res. 2007;13: 382-7.
16. Shevach EM. CD4? CD25? suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2: 389-400.
17. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25? CD4? regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182: 18-32.
18. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol. 2003;3: 223-32.
19. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10: 942-9.
20. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002; 168: 4272-6.
21. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5: 263-74.
22. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6: 295-307.
23. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132: 2328-39.
24. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9: 4404-8.
25. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13: 721s-6s.
26. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(?)CD25(?) Foxp3(?) T cells. Gastroenterology. 2008;135: 234-43.
27. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol. 2006;7: 755-62.
28. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27: 334-48.